← Leaderboards
Comfort Ahenkan Boateng
High Point University
$1,555,000
Attributed
$1,769,000
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $447K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,769,000 · 2
By mechanism
DP1$1,341,000 · 1
R21$428,000 · 1
Top collaborators
- Thomas Mcgowan Keck2 shared
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoReceptor FunctionResponseSignal TransductionFda ApprovedNeuropsychiatric DisorderReceptorReceptor SignalingLibrariesAnalogPharmaceutical PreparationsDrd4 GeneAffinityMolecularAgonistLigandsDesignAntagonistMinisatellite RepeatsMinorGenetic PolymorphismAdrenergic ReceptorAttention Deficit Hyperactivity DisorderDecision Making
Grant awards (5)
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants$447,000
DP1 · FY2025 · DA · contact PI
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants$447,000
DP1 · FY2024 · DA · contact PI
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants$447,000
DP1 · FY2023 · DA · contact PI
Low-Efficacy Dopamine D4 Receptor Partial Agonists for Cocaine Addiction$226,500
R21 · FY2021 · DA · contact PI
Low-Efficacy Dopamine D4 Receptor Partial Agonists for Cocaine Addiction$201,500
R21 · FY2020 · DA · contact PI